To the Honorable Commissioner of Patents and Trademarks: Please record the
1. Name of conveying party(ies):

SANOFI.
174 Avenue de France
75013 Paris
France

Additional name(s) of conveying party(ies) attached? [ ] yes [ X ] no

3. Nature of Conveyance:
[ X ] Assignment    [ ] Merger
[ ] Security Agreement   [ ] Change of Name
[ ] Other

Execution Date (of Assignment): January 20, 2000
(of Application):

Additional name(s) & address(es) attached? [ ] Yes [ X ] No

4. Application number(s) or patent number(s): See attached Appendix A

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)
B. Patent No.(s):

Additional numbers attached? [ X ] Yes [ ] No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Sanofi-Synthelabo Inc.
Internal Address: Patent Department
Michael D. Alexander
Street Address: 9 Great Valley Pkwy
City: Malvern State: PA ZIP 19355

6. Total number of applications and patents involved [ X ]

7. Total fee (37 CFR 3.41): $ 400.00

8. Deposit account number: 19-0091

(Attach Duplicate Copy of this Page)

DO NOT USE THIS SPACE

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document

MICHAEL D. ALEXANDER
Name of Person Signing
Signature
Date 1/27/00

Total number of pages including cover sheet, attachments, and document [ 3 ]

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks
Box Assignments
Washington, D.C. 20231

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project.

(0651-0011), Washington, D.C. 20503
<table>
<thead>
<tr>
<th>Title</th>
<th>Patent No.</th>
<th>Issue Date</th>
<th>Filing Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>TREATMENT AMYOTROPHIC LATERNAL SCLELOSIS</td>
<td>ID 928</td>
<td>25-Oct-96</td>
<td>07-Oct-96</td>
</tr>
<tr>
<td>1,2,6-TETRAHYDROPYRINDINE FOR PEPTATING DRUGS FOR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USE OF 1-(2-NAPHTHYL-2-ETHYL) (+)-1-(2-FLUOROMETHYLPHENYL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AND/OR OXYTOCIN RECEPTOR LIGANDS</td>
<td>ID 939</td>
<td>24-Oct-96</td>
<td>07-Oct-96</td>
</tr>
<tr>
<td>3-PROPONDOLIN-2-ONE DERIVATIVES AS VASOPRESSIN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II-13 RECEPTOR</td>
<td>ID 924</td>
<td>07-Nov-96</td>
<td>07-Oct-96</td>
</tr>
<tr>
<td>STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION</td>
<td>ID 923</td>
<td>30-Oct-96</td>
<td>07-Oct-96</td>
</tr>
<tr>
<td>THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM</td>
<td>ID 916</td>
<td>13-Oct-96</td>
<td>07-Oct-96</td>
</tr>
<tr>
<td>ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOVEL HUMAN NKS RECEPTOR-SELECTIVE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PURIFIED SR-P70 PROTEIN</td>
<td>ID 913</td>
<td>03-Feb-97</td>
<td>12-May-96</td>
</tr>
<tr>
<td>HETEROCYCLIC DERIVATIVE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARRESTIN EMPOLOGING AN N-SUBSTITUTED</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>METHOD OF TREATING OR PREVENT OF CARDIAC</td>
<td>ID 880</td>
<td>30-Jul-96</td>
<td>22-Aug-94</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Pharmaceutical compositions containing imbezaratan and their use as CCK-A agonists
N-triazolyl-2-indolecarboxamides

Method for the preparation of hotline drugs
Use of beta 3-adrenergic receptor agonists

Method for preparing a tetrahydropyridine derivative
Microparticulate form of a tetrahydropyridine derivative

Crystalline forms of a tetrahydropyridine derivative and resulting methods for the crystallization of a
use of benzoxazolyl-1,2,3,6-tetrahydropyridines

Title

Filing Date

Patent No.

Inventor

US Appln No.

International

Issue Date

Patent No.
ASSIGNMENT OF INVENTION

This Assignment is effective the 18th day of May, 1999, between SANOFI a société anonyme of France with offices at 174 Avenue de France, 75013 Paris, France, (hereinafter the "Assignor"), who is the owner of the entire title in the United States patents and patent applications set forth in the attached Appendices and in the inventions covered by said patents and patent applications; and

SANOFI-SYNTHELABO, a société anonyme of France with offices at 174 Avenue de France, 75013 Paris, France (hereinafter the "Assignee"), who wants to acquire the entire title of Assignor in the aforesaid patents and patent applications and the inventions covered thereby.

THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor does hereby assign unto Assignee its entire title in said patents and patent applications, and all divisionals, continuations, continuations-in-part, reissues, re-examinations, substitutes, and extensions thereof and to any Letters Patent which have or may issue based thereon, all of which are encompassed herein by the term "Patents", including all claims for damage for past infringement thereof; the same to be held and enjoyed by Assignee, its successors, and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor had this assignment and sale not been made.

Assignor also agrees that it will, at Assignee's request, render such lawful cooperation and assistance as may be necessary for the proper maintenance and enforcement of said patents and patent applications, provided, however, that Assignor may condition its compliance with such a request on Assignee's agreement to pay Assignor reasonable out-of-pocket expenses in connection therewith.

This document shall be construed, interpreted and applied in accordance with the laws of the State of New York.

In WITNESS WHEREOF, the Assignor has caused it corporate name to be affixed hereto and this instrument to be signed by a duly authorized officer as of the day and year written below.

IN WITNESS WHEREOF, I have hereunto set hand and seal this

18th day of June, 2000.

SANOFI

By

Name: John M. Spinnato
Title: Attorney-in-Fact

(Corporate Seal)